9 terminated. 9 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Terminated 9 |
| Phase 2 | 1 | Terminated 1 |
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants. Nintedanib, AZD5055 - Healthy Subjects | Phase 1 | Terminated | AstraZeneca | 18 | 2023-05-26 | 2024-02-08 |
| Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF AlloRx - Idiopathic Pulmonary Fibrosis | Phase 1 | Terminated | The Foundation for Orthopaedics and Regenerative Medicine | 20 | 2022-07-03 | 2026-10-20 |
| TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis TD-1058, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 1 | Terminated | Theravance Biopharma | 72 | 2020-10-15 | 2022-02-23 |
| A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis IDL-2965 Oral Capsule, Placebos - Healthy Volunteers, Idiopathic Pulmonary Fibrosis | Phase 1 | Terminated | Indalo Therapeutics, Inc. | 6 | 2019-04-16 | 2020-08-04 |
| Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging GSK3008348, Placebo, [18F]-FBA-A20FMDV2 - Idiopathic Pulmonary Fibrosis | Phase 1 | Terminated | GlaxoSmithKline | 8 | 2017-06-13 | 2019-08-12 |
| Cromolyn Detection of Silent Aspiration Cromolyn Sodium - Gastroesophageal Reflux, Respiratory Aspiration | Phase 1 | Terminated | University of California, San Francisco | 16 | 2015-07-01 | 2019-02-15 |
| A Validation and Dosimetry Study of GSK2634673F PET Ligand GSK2634673F - Idiopathic Pulmonary Fibrosis | Phase 1 | Terminated | GlaxoSmithKline | 19 | 2014-01-24 | 2018-06-25 |
| Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs), matched placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 1 | Terminated | Joshua M Hare | 9 | 2013-11-13 | 2021-03-09 |
| Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome Losartan, Zileuton, N-Acetylcysteine - Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis | Phase 1 / Phase 2 | Terminated | National Human Genome Research Institute (NHGRI) | 3 | 2007-04-01 | 2013-08-02 |
Idiopathic Pulmonary Fibrosis (8) · Albinism (1) · Albinism, Oculocutaneous (1) · Fibrosis (1) · Gastroesophageal Reflux (1) · Hermanski-Pudlak Syndrome (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Metabolic Diseases (1) · Platelet Storage Pool Deficiency (1) · Respiratory Aspiration (1)
Respiratory Tract Diseases (9) · Lung Diseases (8) · Lung Diseases, Interstitial (8) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Fibrosis (2) · Amino Acid Metabolism, Inborn Errors (1) · Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Blood Platelet Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Deglutition Disorders (1) · Digestive System Diseases (1) · Esophageal Diseases (1)
Acetylcysteine (1) · Cromolyn Sodium (1) · Erythromycin (1) · GSK3008348 (1) · Losartan (1) · Pravastatin (1) · nintedanib (1) · zileuton (1)
GlaxoSmithKline (2) · AstraZeneca (1) · Indalo Therapeutics, Inc. (1) · Joshua M Hare (1) · National Human Genome Research Institute (NHGRI) (1) · The Foundation for Orthopaedics and Regenerative Medicine (1) · Theravance Biopharma (1) · University of California, San Francisco (1)
United Kingdom (5) · United States (3) · Antigua and Barbuda (1)
Chadwick Prodromos, MD (1) · Homer Boushey, MD (1) · Jim Bush, MRCS FFPM (1) · Marilyn K. Glassberg, MD (1) · Thomas Markello, M.D. (1)
2016 (1), 2019 (1)